Table 4.
The Results of Stratified Analysis in Participants with Proliferative Diabetic Retinopathy
| Y= SFCT, μm | N | Total Cholesterol (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | Triglyceride (mmol/L) | ||||
|---|---|---|---|---|---|---|---|---|---|
| β, 95% CI | P-value | β, 95% CI | P-value | β, 95% CI | P-value | β, 95% CI | P-value | ||
| Gender | |||||||||
| Female | 48 | −19.80 (−38.61, −0.99) | 0.0492 | −98.49 (−163.85, −33.14) | 0.0066 | −23.98 (−46.19, −1.77) | 0.0441 | 24.47 (−7.69, 56.63) | 0.1479 |
| Male | 83 | −12.18 (−30.17, 5.81) | 0.1896 | −31.20 (−82.95, 20.54) | 0.2420 | −11.63 (−32.92, 9.65) | 0.2884 | −1.72 (−35.40, 31.97) | 0.9208 |
| Age (year) | |||||||||
| <53 | 45 | −30.22 (−59.36, −1.08) | 0.0538 | −51.53 (−128.77, 25.71) | 0.2039 | −29.00 (−64.82, 6.82) | 0.1262 | −0.71 (−36.39, 34.97) | 0.9692 |
| ≥53 | 86 | −14.29 (−31.00, 2.41) | 0.0985 | −42.64 (−92.30, 7.03) | 0.0975 | −15.59 (−34.82, 3.63) | 0.1169 | 11.14 (−21.88, 44.16) | 0.5110 |
| PRP | |||||||||
| None | 57 | −13.47 (−32.77, 5.84) | 0.1793 | −95.84 (−161.33, −30.35) | 0.0066 | −12.65 (−35.52, 10.21) | 0.2848 | 34.69 (−9.48, 78.86) | 0.1318 |
| Partial | 27 | −9.92 (−44.14, 24.31) | 0.5879 | −12.18 (−102.96, 78.60) | 0.8002 | −14.04 (−58.44, 30.36) | 0.5550 | −14.62 (−72.10, 42.86) | 0.6334 |
| Whole | 47 | 1.88 (−28.89, 32.64) | 0.9058 | −45.95 (−133.77, 41.86) | 0.3141 | −3.94 (−34.69, 26.81) | 0.8036 | 36.86 (−6.00, 79.73) | 0.1034 |
| Oral glucose-lowering drugs | |||||||||
| No | 33 | −14.93 (−60.04, 30.18) | 0.5263 | −72.23 (−211.16, 66.69) | 0.3243 | −20.03 (−84.82, 44.76) | 0.5536 | 14.98 (−53.27, 83.23) | 0.6732 |
| Yes | 98 | −17.33 (−30.51, −4.14) | 0.0121 | −35.07 (−75.34, 5.20) | 0.0923 | −17.48 (−32.68, −2.28) | 0.0273 | −3.19 (−30.69, 24.31) | 0.8207 |
| Calcium antagonist | |||||||||
| No | 90 | −19.31 (−34.06, −4.56) | 0.0127 | −33.21 (−73.40, 6.97) | 0.1102 | −19.47 (−36.97, −1.97) | 0.0330 | −0.68 (−28.68, 27.32) | 0.9621 |
| Yes | 41 | −19.30 (−58.12, 19.52) | 0.3403 | −57.26 (−199.69, 85.16) | 0.4391 | −20.59 (−60.76, 19.58) | 0.3260 | 11.40 (−47.28, 70.08) | 0.7070 |
| Anti-VEGF therapy | |||||||||
| No | 91 | −16.38 (−31.59, −1.17) | 0.0386 | −53.00 (−96.93, −9.07) | 0.0210 | −16.84 (−34.77, 1.09) | 0.0703 | 10.08 (−16.99, 37.15) | 0.4681 |
| Yes | 40 | −24.29 (−50.84, 2.26) | 0.0881 | −33.63 (−137.75, 70.50) | 0.5339 | −25.21 (−57.15, 6.74) | 0.1377 | −30.42 (−78.58, 17.75) | 0.2301 |
| eGFR (mL/min×1.73m2) | |||||||||
| <60 | 55 | −19.87 (−42.49, 2.76) | 0.0952 | 14.42 (−95.03, 123.88) | 0.7979 | −23.18 (−48.02, 1.66) | 0.0771 | −25.61 (−68.01, 16.80) | 0.2456 |
| ≥60 | 76 | −18.26 (−35.43, −1.08) | 0.0421 | −51.84 (−95.40, −8.29) | 0.0236 | −17.90 (−38.59, 2.79) | 0.0960 | 24.39 (−9.94, 58.72) | 0.1697 |
| Hypertension history | |||||||||
| No | 64 | −15.95 (−34.62, 2.71) | 0.1016 | −54.18 (−114.53, 6.18) | 0.0860 | −13.82 (−33.67, 6.03) | 0.1799 | 18.59 (−17.86, 55.04) | 0.3234 |
| Yes | 67 | −20.32 (−45.64, 5.01) | 0.1230 | −33.20 (−96.86, 30.45) | 0.3122 | −22.99 (−52.89, 6.92) | 0.1391 | −4.63 (−43.84, 34.57) | 0.8179 |
| Chronic kidney disease history | |||||||||
| No | 96 | −14.57 (−28.57, −0.56) | 0.0453 | −39.69 (−76.36, −3.02) | 0.0374 | −12.86 (−29.24, 3.51) | 0.1280 | 7.64 (−17.68, 32.97) | 0.5560 |
| Yes | 35 | 8.25 (−43.39, 59.88) | 0.7597 | 18.59 (−191.86, 229.04) | 0.8654 | 7.30 (−58.29, 72.89) | 0.8309 | 13.03 (−50.67, 76.73) | 0.6955 |
Notes: Each stratification was adjusted for all factors (age, gender, ocular axial length, PRP, duration of diabetes, serum creatinine, DBP, HbA1c, anti-VEGF therapy, oral glucose-lowering drugs, and oral calcium antagonists), except the stratification factor itself.
Abbreviations: CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; SFCT, subfoveal choroidal thickness; VEGF, vascular endothelial growth factor; PRP, panretinal photocoagulation.